Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategyPHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. NASDAQ:MDCX (“Medicus” or the “Com…